Acrigen Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Acrigen Biosciences's estimated annual revenue is currently $1.9M per year.
- Acrigen Biosciences's estimated revenue per employee is $155,000
Employee Data
- Acrigen Biosciences has 12 Employees.
- Acrigen Biosciences grew their employee count by -33% last year.
Acrigen Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder, CEO, & President | Reveal Email/Phone |
2 | VP Research and Operations | Reveal Email/Phone |
3 | Chief Technology Officer | Reveal Email/Phone |
4 | Scientist | Reveal Email/Phone |
Acrigen Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Acrigen Biosciences?
Acrigen Biosciences is an early-stage biotech company developing technologies to improve the efficiency and enhance the safety of CRISPR-Cas based gene editing. CRISPR-Cas system which enables the precise enzymatic editing of genes is one of the most exciting and promising techniques to be developed in the last few years with the capability to prevent or cure many devastating diseases. The current challenge is to optimize the gene editing process to eliminates unwanted side effects and unanticipated editing in a patient. Acrigen Biosciences technology is based on a class of proteins, anti-CRISPR or Acr proteins, that precisely deactivate the Cas proteins serving as a gene editing “off switchâ€. The company is co-founded by Professor Joseph Bondy-Denomy, currently at UCSF, who discovered Acr proteins. Acrigen Biosciences is the first company developing Acr proteins to better control the CRISPR-Cas gene editing process to create an improved CRISPR gene editing platform for safe and effective gene therapies.
keywords:N/A
N/A
Total Funding
12
Number of Employees
$1.9M
Revenue (est)
-33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Berkeley
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.8M | 12 | 9% | N/A |
#2 | $1M | 12 | -25% | N/A |
#3 | $1M | 12 | 0% | N/A |
#4 | $1.9M | 12 | 9% | N/A |
#5 | $1.2M | 12 | 71% | N/A |